

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) An isolated A-polynucleotide molecule having a promoter activity for a polynucleotide encoding the amino acid sequence polypeptide of SEQ ID NO:2, wherein said polynucleotide molecule comprises a polynucleotide sequence selected from the group consisting of:

(a) the polynucleotide sequence of SEQ ID NO:17,

(b) a polynucleotide sequence of SEQ ID NO:17 in which 1 to 10 nucleotides are substituted, deleted, and/or inserted,

(c) the polynucleotide ~~and comprising a nucleotide~~ sequence consisting of nucleotides 3253 to 5023 of a 3253rd to 5023rd nucleotides in SEQ ID NO:17, and

(d) a polynucleotide ~~or a nucleotide~~ sequence consisting of nucleotides 3253 to 5023 of the 3253rd to the 5023rd nucleotides in SEQ ID NO:17 in which 1 to 10 nucleotides are substituted, deleted, and/or inserted.

2. (currently amended) The A-polynucleotide molecule according to claim 1, wherein said polynucleotide molecule comprises the polynucleotide ~~comprising a nucleotide~~ sequence of SEQ ID NO:17 or a polynucleotide ~~a nucleotide~~ sequence consisting of a nucleotide ~~sequence of~~ SEQ ID NO:17 in which 1 to 10 nucleotides are substituted, deleted, and/or inserted.

3. (currently amended) The A-polynucleotide molecule according to claim 1, wherein said polynucleotide molecule comprises the polynucleotide ~~comprising the~~

~~nucleotide~~-sequence consisting of nucleotides 3253 to 5023 of ~~the 3253rd to 5023rd~~
~~nucleotides in~~ SEQ ID NO:17 or the polynucleotide ~~nucleotide~~-sequence of SEQ ID NO:17.

4. (currently amended) An expression vector comprising the polynucleotide
molecule according to any one of claims 1 to 3.

5. (original) A cell transfected with the expression vector according to claim 4.

6-7. (canceled).

8. (original) A method for analyzing a test compound about whether or not the
test compound inhibits the promoter activity of the polynucleotide according to any one of
claims 1 to 3, comprising (1) a step of allowing the test compound to contact with the cell
according to claim 5 and (2) a step of detecting the promoter activity.

9. (original) A method for screening a substance suppressing the expression of a
polypeptide of SEQ ID NO:2, comprising the analyzing step by the method according to
claim 8 and a step of selecting a substance inhibiting the promoter activity.

10. (canceled).

11. (original) A method for producing a pharmaceutical composition for the
treatment and/or prevention of chronic renal failure, comprising the analyzing step by the
method according to claim 8 and a formulation step.

12. (new) The polynucleotide molecule according to claim 1, wherein said
polynucleotide molecule consists of the polynucleotide sequence of nucleotides 3253 to 5023
of SEQ ID NO:17 or the polynucleotide sequence of SEQ ID NO:17.